Beilstein J. Org. Chem. 2021, 17, 1814–1827, doi:10.3762/bjoc.17.124
Graphical Abstract
Figure 1: Schematic overview of fungal interactions in the environment. Fungi can be found in essentially all...
Figure 2: Fungal derived bioactive natural compounds with ecological and/or economic relevance.
Figure 3: Gliotoxin biosynthetic gene cluster and it major biosynthetic transformations: Gliotoxin (5) is the...
Figure 4: Amoebicidal secondary metabolites trypacidin and fumagillin of Aspergillus fumigatus.
Figure 5: Intermediates of the DHN-melanin biosynthesis in Aspergillus fumigatus.
Figure 6: Intermediates and products of the fumigaclavine C biosynthesis.
Figure 7: Bioactive secondary metabolites of Aspergillus fumigatus.
Figure 8: Helvolic acid gene cluster of A. fumigatus.
Beilstein J. Org. Chem. 2021, 17, 1828–1848, doi:10.3762/bjoc.17.125
Graphical Abstract
Figure 1: A schematic representation of 16-mer ASOs in different designs. White circles represent unmodified ...
Figure 2: Structures of 5-(1-propargylamino)-2’-deoxyuridine (A) and 2’-aminoethoxy-5-propargylaminouridine (...
Beilstein J. Org. Chem. 2021, 17, 1849–1938, doi:10.3762/bjoc.17.126
Graphical Abstract
Scheme 1: Schematic overview of transition metals studied in C–H activation processes.
Scheme 2: (A) Known biological activities related to benzimidazole-based compounds; (B and C) an example of a...
Scheme 3: (A) Known biological activities related to quinoline-based compounds; (B and C) an example of a sca...
Scheme 4: (A) Known biological activities related to sulfur-containing compounds; (B and C) an example of a s...
Scheme 5: (A) Known biological activities related to aminoindane derivatives; (B and C) an example of a scand...
Scheme 6: (A) Known biological activities related to norbornane derivatives; (B and C) an example of a scandi...
Scheme 7: (A) Known biological activities related to aniline derivatives; (B and C) an example of a titanium-...
Scheme 8: (A) Known biological activities related to cyclohexylamine derivatives; (B) an example of an intram...
Scheme 9: (A) Known biologically active benzophenone derivatives; (B and C) photocatalytic oxidation of benzy...
Scheme 10: (A) Known bioactive fluorine-containing compounds; (B and C) vanadium-mediated C(sp3)–H fluorinatio...
Scheme 11: (A) Known biologically active Lythraceae alkaloids; (B) synthesis of (±)-decinine (30).
Scheme 12: (A) Synthesis of (R)- and (S)-boehmeriasin (31); (B) synthesis of phenanthroindolizidines by vanadi...
Scheme 13: (A) Known bioactive BINOL derivatives; (B and C) vanadium-mediated oxidative coupling of 2-naphthol...
Scheme 14: (A) Known antiplasmodial imidazopyridazines; (B) practical synthesis of 41.
Scheme 15: (A) Gold-catalyzed drug-release mechanism using 2-alkynylbenzamides; (B and C) chromium-mediated al...
Scheme 16: (A) Examples of anti-inflammatory benzaldehyde derivatives; (B and C) chromium-mediated difunctiona...
Scheme 17: (A and B) Manganese-catalyzed chemoselective intramolecular C(sp3)–H amination; (C) late-stage modi...
Scheme 18: (A and B) Manganese-catalyzed C(sp3)–H amination; (C) late-stage modification of a leelamine deriva...
Scheme 19: (A) Known bioactive compounds containing substituted N-heterocycles; (B and C) manganese-catalyzed ...
Scheme 20: (A) Known indoles that present GPR40 full agonist activity; (B and C) manganese-catalyzed C–H alkyl...
Scheme 21: (A) Examples of known biaryl-containing drugs; (B and C) manganese-catalyzed C–H arylation through ...
Scheme 22: (A) Known zidovudine derivatives with potent anti-HIV properties; (B and C) manganese-catalyzed C–H...
Scheme 23: (A and B) Manganese-catalyzed C–H organic photo-electrosynthesis; (C) late-stage modification.
Scheme 24: (A) Example of a known antibacterial silylated dendrimer; (B and C) manganese-catalyzed C–H silylat...
Scheme 25: (A and B) Fe-based small molecule catalyst applied for selective aliphatic C–H oxidations; (C) late...
Scheme 26: (A) Examples of naturally occurring gracilioethers; (B) the first total synthesis of gracilioether ...
Scheme 27: (A and B) Selective aliphatic C–H oxidation of amino acids; (C) late-stage modification of proline-...
Scheme 28: (A) Examples of Illicium sesquiterpenes; (B) first chemical synthesis of (+)-pseudoanisatin (80) in...
Scheme 29: (A and B) Fe-catalyzed deuteration; (C) late-stage modification of pharmaceuticals.
Scheme 30: (A and B) Biomimetic Fe-catalyzed aerobic oxidation of methylarenes to benzaldehydes (PMHS, polymet...
Scheme 31: (A) Known tetrahydroquinolines with potential biological activities; (B and C) redox-selective Fe c...
Scheme 32: (A) Known drugs containing a benzofuran unit; (B and C) Fe/Cu-catalyzed tandem O-arylation to acces...
Scheme 33: (A) Known azaindolines that act as M4 muscarinic acetylcholine receptor agonists; (B and C) intramo...
Scheme 34: (A) Known indolinones with anticholinesterase activity; (B and C) oxidative C(sp3)–H cross coupling...
Scheme 35: (A and B) Cobalt-catalyzed C–H alkenylation of C-3-peptide-containing indoles; (C) derivatization b...
Scheme 36: (A) Cobalt-Cp*-catalyzed C–H methylation of known drugs; (B and C) scope of the o-methylated deriva...
Scheme 37: (A) Known lasalocid A analogues; (B and C) three-component cobalt-catalyzed C–H bond addition; (D) ...
Scheme 38: (A and B) Cobalt-catalyzed C(sp2)–H amidation of thiostrepton.
Scheme 39: (A) Known 4H-benzo[d][1,3]oxazin-4-one derivatives with hypolipidemic activity; (B and C) cobalt-ca...
Scheme 40: (A and B) Cobalt-catalyzed C–H arylation of pyrrole derivatives; (C) application for the synthesis ...
Scheme 41: (A) Known 2-phenoxypyridine derivatives with potent herbicidal activity; (B and C) cobalt-catalyzed...
Scheme 42: (A) Natural cinnamic acid derivatives; (B and C) cobalt-catalyzed C–H carboxylation of terminal alk...
Scheme 43: (A and B) Cobalt-catalyzed C–H borylation; (C) application to the synthesis of flurbiprofen.
Scheme 44: (A) Benzothiazoles known to present anticonvulsant activities; (B and C) cobalt/ruthenium-catalyzed...
Scheme 45: (A and B) Cobalt-catalyzed oxygenation of methylene groups towards ketone synthesis; (C) synthesis ...
Scheme 46: (A) Known anticancer tetralone derivatives; (B and C) cobalt-catalyzed C–H difluoroalkylation of ar...
Scheme 47: (A and B) Cobalt-catalyzed C–H thiolation; (C) application in the synthesis of quetiapine (153).
Scheme 48: (A) Known benzoxazole derivatives with anticancer, antifungal, and antibacterial activities; (B and...
Scheme 49: (A and B) Cobalt-catalyzed C–H carbonylation of naphthylamides; (C) BET inhibitors 158 and 159 tota...
Scheme 50: (A) Known bioactive pyrrolo[1,2-a]quinoxalin-4(5H)-one derivatives; (B and C) cobalt-catalyzed C–H ...
Scheme 51: (A) Known antibacterial cyclic sulfonamides; (B and C) cobalt-catalyzed C–H amination of propargyli...
Scheme 52: (A and B) Cobalt-catalyzed intramolecular 1,5-C(sp3)–H amination; (C) late-stage functionalization ...
Scheme 53: (A and B) Cobalt-catalyzed C–H/C–H cross-coupling between benzamides and oximes; (C) late-state syn...
Scheme 54: (A) Known anticancer natural isoquinoline derivatives; (B and C) cobalt-catalyzed C(sp2)–H annulati...
Scheme 55: (A) Enantioselective intramolecular nickel-catalyzed C–H activation; (B) bioactive obtained motifs;...
Scheme 56: (A and B) Nickel-catalyzed α-C(sp3)–H arylation of ketones; (C) application of the method using kno...
Scheme 57: (A and B) Nickel-catalyzed C(sp3)–H acylation of pyrrolidine derivatives; (C) exploring the use of ...
Scheme 58: (A) Nickel-catalyzed C(sp3)–H arylation of dioxolane; (B) library of products obtained from biologi...
Scheme 59: (A) Intramolecular enantioselective nickel-catalyzed C–H cycloalkylation; (B) product examples, inc...
Scheme 60: (A and B) Nickel-catalyzed C–H deoxy-arylation of azole derivatives; (C) late-stage functionalizati...
Scheme 61: (A and B) Nickel-catalyzed decarbonylative C–H arylation of azole derivatives; (C) application of t...
Scheme 62: (A and B) Another important example of nickel-catalyzed C–H arylation of azole derivatives; (C) app...
Scheme 63: (A and B) Another notable example of a nickel-catalyzed C–H arylation of azole derivatives; (C) lat...
Scheme 64: (A and B) Nickel-based metalorganic framework (MOF-74-Ni)-catalyzed C–H arylation of azole derivati...
Scheme 65: (A) Known commercially available benzothiophene-based drugs; (B and C) nickel-catalyzed C–H arylati...
Scheme 66: (A) Known natural tetrahydrofuran-containing substances; (B and C) nickel-catalyzed photoredox C(sp3...
Scheme 67: (A and B) Another notable example of a nickel-catalyzed photoredox C(sp3)–H alkylation/arylation; (...
Scheme 68: (A) Electrochemical/nickel-catalyzed C–H alkoxylation; (B) achieved scope, including three using na...
Scheme 69: (A) Enantioselective photoredox/nickel catalyzed C(sp3)–H arylation; (B) achieved scope, including ...
Scheme 70: (A) Known commercially available trifluoromethylated drugs; (B and C) nickel-catalyzed C–H trifluor...
Scheme 71: (A and B) Stereoselective nickel-catalyzed C–H difluoroalkylation; (C) late-stage functionalization...
Scheme 72: (A) Cu-mediated ortho-amination of oxalamides; (B) achieved scope, including derivatives obtained f...
Scheme 73: (A) Electro-oxidative copper-mediated amination of 8-aminoquinoline-derived amides; (B) achieved sc...
Scheme 74: (A and B) Cu(I)-mediated C–H amination with oximes; (C) derivatization using telmisartan (241) as s...
Scheme 75: (A and B) Cu-mediated amination of aryl amides using ammonia; (C) late-stage modification of proben...
Scheme 76: (A and B) Synthesis of purine nucleoside analogues using copper-mediated C(sp2)–H activation.
Scheme 77: (A) Copper-mediated annulation of acrylamide; (B) achieved scope, including the synthesis of the co...
Scheme 78: (A) Known bioactive compounds containing a naphthyl aryl ether motif; (B and C) copper-mediated eth...
Scheme 79: (A and B) Cu-mediated alkylation of N-oxide-heteroarenes; (C) late-stage modification.
Scheme 80: (A) Cu-mediated cross-dehydrogenative coupling of polyfluoroarenes and alkanes; (B) scope from know...
Scheme 81: (A) Known anticancer acrylonitrile compounds; (B and C) Copper-mediated cyanation of unactivated al...
Scheme 82: (A) Cu-mediated radiofluorination of 8-aminoquinoline-derived aryl amides; (B) achieved scope, incl...
Scheme 83: (A) Examples of natural β-carbolines; (B and C) an example of a zinc-catalyzed C–H functionalizatio...
Scheme 84: (A) Examples of anticancer α-aminophosphonic acid derivatives; (B and C) an example of a zinc-catal...
Beilstein J. Org. Chem. 2021, 17, 1939–1951, doi:10.3762/bjoc.17.127
Graphical Abstract
Figure 1: Examples of indazole natural products (1 and 2) and synthetic biologically active indazole derivati...
Scheme 1: Synthetic approaches to N-1 substituted indazole derivatives [12-14].
Scheme 2: N-Alkylation of indazole 9 under Mitsunobu conditions shows a strong preference (ratio N-1 (10):N-2...
Figure 2: Observation of a 1H–13C correlation between the C-7a (blue circle) or C-3 (red circle) atom of the ...
Figure 3: C-3 substituted indazole derivatives (12–24) employed to investigate C-3 substituent effects on ind...
Scheme 3: Proposed mechanism for the regioselective N-1 alkylation of indazoles 9, 19, and 21–24 in the prese...
Beilstein J. Org. Chem. 2021, 17, 1952–1980, doi:10.3762/bjoc.17.128
Graphical Abstract
Figure 1: Coumarin-derived commercially available drugs.
Figure 2: Inhibition of acetylcholinesterase by coumarin derivatives.
Scheme 1: Michael addition of 4-hydroxycoumarins 1 to α,β‐unsaturated enones 2.
Scheme 2: Organocatalytic conjugate addition of 4-hydroxycoumarin 1 to α,β-unsaturated aldehydes 2 followed b...
Scheme 3: Synthesis of 3,4-dihydrocoumarin derivatives 10 through decarboxylative and dearomatizative cascade...
Scheme 4: Total synthesis of (+)-smyrindiol (17).
Scheme 5: Michael addition of 4-hydroxycoumarin (1) to enones 2 through a bifunctional modified binaphthyl or...
Scheme 6: Michael addition of ketones 20 to 3-aroylcoumarins 19 using a cinchona alkaloid-derived primary ami...
Scheme 7: Enantioselective reaction of cyclopent-2-enone-derived MBH alcohols 24 with 4-hydroxycoumarins 1.
Scheme 8: Sequential Michael addition/hydroalkoxylation one-pot approach to annulated coumarins 28 and 30.
Scheme 9: Michael addition of 4-hydroxycoumarins 1 to enones 2 using a binaphthyl diamine catalyst 31.
Scheme 10: Asymmetric Michael addition of 4-hydroxycoumarin 1 with α,β-unsaturated ketones 2 catalyzed by a ch...
Scheme 11: Catalytic asymmetric β-C–H functionalization of ketones via enamine oxidation.
Scheme 12: Enantioselective synthesis of polycyclic coumarin derivatives 37 catalyzed by an primary amine-imin...
Scheme 13: Allylic alkylation reaction between 3-cyano-4-methylcoumarins 39 and MBH carbonates 40.
Scheme 14: Enantioselective synthesis of cyclopropa[c]coumarins 45.
Scheme 15: NHC-catalyzed lactonization of 2-bromoenals 46 with 4-hydroxycoumarin (1).
Scheme 16: NHC-catalyzed enantioselective synthesis of dihydrocoumarins 51.
Scheme 17: Domino reaction of enals 2 with hydroxylated malonate 53 catalyzed by NHC 55.
Scheme 18: Oxidative [4 + 2] cycloaddition of enals 57 to coumarins 56 catalyzed by NHC 59.
Scheme 19: Asymmetric [3 + 2] cycloaddition of coumarins 43 to azomethine ylides 60 organocatalyzed by quinidi...
Scheme 20: Synthesis of α-benzylaminocoumarins 64 through Mannich reaction between 4-hydroxycoumarins (1) and ...
Scheme 21: Asymmetric addition of malonic acid half-thioesters 67 to coumarins 66 using the sulphonamide organ...
Scheme 22: Enantioselective 1,4-addition of azadienes 71 to 3-homoacyl coumarins 70.
Scheme 23: Michael addition/intramolecular cyclization of 3-acylcoumarins 43 to 3-halooxindoles 74.
Scheme 24: Enantioselective synthesis of 3,4-dihydrocoumarins 78 catalyzed by squaramide 73.
Scheme 25: Organocatalyzed [4 + 2] cycloaddition between 2,4-dienals 79 and 3-coumarincarboxylates 43.
Scheme 26: Enantioselective one-pot Michael addition/intramolecular cyclization for the synthesis of spiro[dih...
Scheme 27: Michael/hemiketalization addition enantioselective of hydroxycoumarins (1) to: (a) enones 2 and (b)...
Scheme 28: Synthesis of 2,3-dihydrofurocoumarins 89 through Michael addition of 4-hydroxycoumarins 1 to β-nitr...
Scheme 29: Synthesis of pyrano[3,2-c]chromene derivatives 93 via domino reaction between 4-hydroxycoumarins (1...
Scheme 30: Conjugated addition of 4-hydroxycoumarins 1 to nitroolefins 95.
Scheme 31: Michael addition of 4-hydroxycoumarin 1 to α,β-unsaturated ketones 2 promoted by primary amine thio...
Scheme 32: Enantioselective synthesis of functionalized pyranocoumarins 99.
Scheme 33: 3-Homoacylcoumarin 70 as 1,3-dipole for enantioselective concerted [3 + 2] cycloaddition.
Scheme 34: Synthesis of warfarin derivatives 107 through addition of 4-hydroxycoumarins 1 to β,γ-unsaturated α...
Scheme 35: Asymmetric multicatalytic reaction sequence of 2-hydroxycinnamaldehydes 109 with 4-hydroxycoumarins ...
Scheme 36: Mannich asymmetric addition of cyanocoumarins 39 to isatin imines 112 catalyzed by the amide-phosph...
Scheme 37: Enantioselective total synthesis of (+)-scuteflorin A (119).
Beilstein J. Org. Chem. 2021, 17, 1981–2025, doi:10.3762/bjoc.17.129
Graphical Abstract
Figure 1: Overview of the methods available for the synthesis of polysaccharides. For each method, advantages...
Figure 2: Overview of the classes of polysaccharides discussed in this review. Each section deals with polysa...
Scheme 1: Enzymatic and chemical polymerization approaches provide cellulose oligomers with a non-uniform dis...
Scheme 2: AGA of a collection of cellulose analogues obtained using BBs 6–9. Specifically placed modification...
Figure 3: Chemical structure of the different branches G, X, L, F commonly found in XGs. Names are given foll...
Scheme 3: AGA of XG analogues with defined side chains. The AGA cycle includes coupling (TMSOTf), Fmoc deprot...
Figure 4: Synthetic strategies and issues associated to the formation of the β(1–3) linkage.
Scheme 4: Convergent synthesis of β(1–3)-glucans using a regioselective glycosylation strategy.
Scheme 5: DMF-mediated 1,2-cis glycosylation. A) General mechanism and B) examples of α-glucans prepared usin...
Scheme 6: Synergistic glycosylation strategy employing a nucleophilic modulation strategy (TMSI and Ph3PO) in...
Scheme 7: Different approaches to produce xylans. A) Polymerization techniques including ROP, and B) enzymati...
Scheme 8: A) Synthesis of arabinofuranosyl-decorated xylan oligosaccharides using AGA. Representative compoun...
Scheme 9: Chemoenzymatic synthesis of COS utilizing a lysozyme-catalyzed transglycosylation reaction followed...
Scheme 10: Synthesis of COS using an orthogonal glycosylation strategy based on the use of two different LGs.
Scheme 11: Orthogonal N-PGs permitted the synthesis of COS with different PA.
Scheme 12: AGA of well-defined COS with different PA using two orthogonally protected BBs. The AGA cycle inclu...
Scheme 13: A) AGA of β(1–6)-N-acetylglucosamine hexasaccharide and dodecasaccharide. AGA includes cycles of co...
Figure 5: ‘Double-faced’ chemistry exemplified for ᴅ-Man and ʟ-Rha. Constructing β-Man linkages is considerab...
Figure 6: Implementation of a capping step after each glycosylation cycle for the AGA of a 50mer oligomannosi...
Scheme 14: AGA enabled the synthesis of a linear α(1–6)-mannoside 100mer 93 within 188 h and with an average s...
Scheme 15: The 151mer branched polymannoside was synthesized by a [30 + 30 + 30 + 30 + 31] fragment coupling. ...
Figure 7: PG stereocontrol strategy to obtain β-mannosides. A) The mechanism of the β-mannosylation reaction ...
Scheme 16: A) Mechanism of 1,2-cis stereoselective glycosylation using ManA donors. Once the ManA donor is act...
Figure 8: A) The preferred 4H3 conformation of the gulosyl oxocarbenium ion favors the attack of the alcohol ...
Scheme 17: AGA of type I rhamnans up to 16mer using disaccharide BB 115 and CNPiv PG. The AGA cycle includes c...
Figure 9: Key BBs for the synthesis of the O-antigen of Bacteroides vulgatus up to a 128mer (A) and the CPS o...
Figure 10: Examples of type I and type II galactans synthesized to date.
Figure 11: A) The DTBS PG stabilizes the 3H4 conformation of the Gal oxocarbenium ion favoring the attack of t...
Figure 12: Homogalacturonan oligosaccharides synthesized to date. Access to different patterns of methyl-ester...
Figure 13: GlfT2 from Mycobacterium tuberculosis catalyzes the sequential addition of UPD-Galf donor to a grow...
Figure 14: The poor reactivity of acceptor 137 hindered a stepwise synthesis of the linear galactan backbone a...
Scheme 18: AGA of a linear β(1–5) and β(1–6)-linked galactan 20mer. The AGA cycle includes coupling (NIS/TfOH)...
Figure 15: The 92mer arabinogalactan was synthesized using a [31 + 31 + 30] fragment coupling between a 31mer ...
Scheme 19: Synthesis of the branched arabinofuranose fragment using a six component one-pot synthesis. i) TTBP...
Figure 16: A) Chemical structure and SNFG of the representative disaccharide units forming the GAG backbones, ...
Figure 17: Synthetic challenges associated to the H/HS synthesis.
Scheme 20: Degradation of natural heparin and heparosan generated valuable disaccharides 150 and 151 that can ...
Scheme 21: A) The one-step conversion of cyanohydrin 156 to ʟ-iduronamide 157 represent the key step for the s...
Scheme 22: A) Chemoenzymatic synthesis of heparin structures, using different types of UDP activated natural a...
Scheme 23: Synthesis of the longest synthetic CS chain 181 (24mer) using donor 179 and acceptor 180 in an iter...
Scheme 24: AGA of a collection of HA with different lengths. The AGA cycle includes coupling (TfOH) and Lev de...
Beilstein J. Org. Chem. 2021, 17, 2026–2027, doi:10.3762/bjoc.17.130
Beilstein J. Org. Chem. 2021, 17, 2028–2050, doi:10.3762/bjoc.17.131
Graphical Abstract
Figure 1: Examples of anthracene derivatives and their applications.
Scheme 1: Rhodium-catalyzed oxidative coupling reactions of arylboronic acids with internal alkynes.
Scheme 2: Rhodium-catalyzed oxidative benzannulation reactions of 1-adamantoyl-1-naphthylamines with internal...
Scheme 3: Gold/bismuth-catalyzed cyclization of o-alkynyldiarylmethanes.
Scheme 4: [2 + 2 + 2] Cyclotrimerization reactions with alkynes/nitriles in the presence of nickel and cobalt...
Scheme 5: Cobalt-catalyzed [2 + 2 + 2] cyclotrimerization reactions with bis(trimethylsilyl)acetylene (23).
Scheme 6: [2 + 2 + 2] Alkyne-cyclotrimerization reactions catalyzed by a CoCl2·6H2O/Zn reagent.
Scheme 7: Pd(II)-catalyzed sp3 C–H alkenylation of diphenyl carboxylic acids with acrylates.
Scheme 8: Pd(II)-catalyzed sp3 C–H arylation with o-tolualdehydes and aryl iodides.
Scheme 9: Alkylation of arenes with aromatic aldehydes in the presence of acetyl bromide and ZnBr2/SiO2.
Scheme 10: BF3·H2O-catalyzed hydroxyalkylation of arenes with aromatic dialdehyde 44.
Scheme 11: Bi(OTf)3-promoted Friedel–Crafts alkylation of triarylmethanes and aromatic acylals and of arenes a...
Scheme 12: Reduction of anthraquinones by using Zn/pyridine or Zn/NaOH reductive methods.
Scheme 13: Two-step route to novel substituted Indenoanthracenes.
Scheme 14: Synthesis of 1,8-diarylanthracenes through Suzuki–Miyaura coupling reaction in the presence of Pd-P...
Scheme 15: Synthesis of five new substituted anthracenes by using LAH as reducing agent.
Scheme 16: One-pot procedure to synthesize substituted 9,10-dicyanoanthracenes.
Scheme 17: Reduction of bromoanthraquinones with NaBH4 in alkaline medium.
Scheme 18: In(III)-catalyzed reductive-dehydration intramolecular cycloaromatization of 2-benzylic aromatic al...
Scheme 19: Acid-catalyzed cyclization of new O-protected ortho-acetal diarylmethanols.
Scheme 20: Lewis acid-mediated regioselective cyclization of asymmetric diarylmethine dipivalates and diarylme...
Scheme 21: BF3·OEt2/CF3SO3H-mediated cyclodehydration reactions of 2-(arylmethyl)benzaldehydes and 2-(arylmeth...
Scheme 22: Synthesis of 2,3,6,7-anthracenetetracarbonitrile (90) by double Wittig reaction followed by deprote...
Scheme 23: Homo-elongation protocol for the synthesis of substituted acene diesters/dinitriles.
Scheme 24: Synthesis of two new parental BN anthracenes via borylative cyclization.
Scheme 25: Synthesis of substituted anthracenes from a bifunctional organomagnesium alkoxide.
Scheme 26: Palladium-catalyzed tandem C–H activation/bis-cyclization of propargylic carbonates.
Scheme 27: Ruthenium-catalyzed C–H arylation of acetophenone derivatives with arenediboronates.
Scheme 28: Pd-catalyzed intramolecular cyclization of (Z,Z)-p-styrylstilbene derivatives.
Scheme 29: AuCl-catalyzed double cyclization of diiodoethynylterphenyl compounds.
Scheme 30: Iodonium-induced electrophilic cyclization of terphenyl derivatives.
Scheme 31: Oxidative photocyclization of 1,3-distyrylbenzene derivatives.
Scheme 32: Oxidative cyclization of 2,3-diphenylnaphthalenes.
Scheme 33: Suzuki-Miyaura/isomerization/ring closing metathesis strategy to synthesize benz[a]anthracenes.
Scheme 34: Green synthesis of oxa-aza-benzo[a]anthracene and oxa-aza-phenanthrene derivatives.
Scheme 35: Triple benzannulation of substituted naphtalene via a 1,3,6-naphthotriyne synthetic equivalent.
Scheme 36: Zinc iodide-catalyzed Diels–Alder reactions with 1,3-dienes and aroyl propiolates followed by intra...
Scheme 37: H3PO4-promoted intramolecular cyclization of substituted benzoic acids.
Scheme 38: Palladium-catalyzed intermolecular direct acylation of aromatic aldehydes and o-iodoesters.
Scheme 39: Cycloaddition/oxidative aromatization of quinone and β-enamino esters.
Scheme 40: ʟ-Proline-catalyzed [4 + 2] cycloaddition reaction of naphthoquinones and α,β-unsaturated aldehydes....
Scheme 41: Iridium-catalyzed [2 + 2 + 2] cycloaddition of a 1,2-bis(propiolyl)benzene derivative with alkynes.
Scheme 42: Synthesis of several anthraquinone derivatives by using InCl3 and molecular iodine.
Scheme 43: Indium-catalyzed multicomponent reactions employing 2-hydroxy-1,4-naphthoquinone (186), β-naphthol (...
Scheme 44: Synthesis of substituted anthraquinones catalyzed by an AlCl3/MeSO3H system.
Scheme 45: Palladium(II)-catalyzed/visible light-mediated synthesis of anthraquinones.
Scheme 46: [4 + 2] Anionic annulation reaction for the synthesis of substituted anthraquinones.
Beilstein J. Org. Chem. 2021, 17, 2051–2066, doi:10.3762/bjoc.17.132
Graphical Abstract
Figure 1: Some commercial Ru-based catalysts used in the current work.
Figure 2: Synthesis of divinylated cyclopentane-fused isoxazolines [41].
Figure 3: Various fluorine-containing olefins used in the current work.
Scheme 1: Cross-metathesis of divinylated isoxazoline (±)-4 with 1,1,1,3,3,3-hexafluoropropan-2-yl acrylate (...
Scheme 2: Cross-metathesis of divinylated isoxazoline (±)-4 with 2,2,3,3,4,4,4-heptafluorobutyl acrylate (7d)....
Scheme 3: Cross-metathesis of divinylated isoxazoline (±)-4 with 2,2,2-trifluoroethyl acrylate (7e).
Scheme 4: Cross-metathesis of divinylated isoxazoline (±)-4 with 1,1,1-trifluoro-2-(trifluoromethyl)pent-4-en...
Scheme 5: Cross-metathesis of divinylated isoxazoline (±)-4 with 8-(allyloxy)-1,1,1,2,2,3,3,4,4,5,5,6,6-tride...
Scheme 6: Cross-metathesis of divinylated isoxazoline (±)-4 with 4-fluorostyrene (7h).
Scheme 7: Selective CM of divinylated isoxazoline (±)-5 with 1,1,1,3,3,3-hexafluoropropan-2-yl acrylate (7c).
Scheme 8: Cross-metathesis of divinylated isoxazoline (±)-5 with 2,2,3,3,4,4,4-heptafluorobutyl acrylate (7d)....
Scheme 9: Cross-metathesis of divinylated isoxazoline (±)-5 with 2,2,2-trifluoroethyl acrylate (7e).
Scheme 10: Cross-metathesis of divinylated isoxazoline (±)-5 with 1,1,1-trifluoro-2-(trifluoromethyl)pent-4-en...
Scheme 11: Cross-metathesis of divinylated isoxazoline (±)-5 with 8-(allyloxy)-1,1,1,2,2,3,3,4,4,5,5,6,6-tride...
Scheme 12: Cross-metathesis of divinylated isoxazoline (±)-5 with 4-fluorostyrene (7h).
Scheme 13: Cross-metathesis of divinylated isoxazoline (±)-6 with 1,1,1,3,3,3-hexafluoropropan-2-yl acrylate (...
Scheme 14: Cross-metathesis of divinylated isoxazoline (±)-6 with 2,2,3,3,4,4,4-heptafluorobutyl acrylate (7d)....
Scheme 15: Cross-metathesis of divinylated isoxazoline (±)-6 with 2,2,2-trifluoroethyl acrylate (7e).
Scheme 16: Cross-metathesis of divinylated isoxazoline (±)-6 with 1,1,1-trifluoro-2-(trifluoromethyl)pent-4-en...
Scheme 17: Cross-metathesis of divinylated isoxazoline (±)-6 with 8-(allyloxy)-1,1,1,2,2,3,3,4,4,5,5,6,6-tride...
Scheme 18: Cross-metathesis of divinylated isoxazoline (±)-6 with 4-fluorostyrene (7h).
Figure 4: Chemoselective CM reaction due to steric hindrance.
Beilstein J. Org. Chem. 2021, 17, 2067–2076, doi:10.3762/bjoc.17.133
Graphical Abstract
Scheme 1: Investigated NIR dyes.
Scheme 2: Other used chemicals.
Scheme 3: Synthetic routes to compounds Ca, Cb, and CNa.
Scheme 4: Synthetic routes to CI1, CI3, CI4, and CI6–CI9.
Scheme 5: The metathesis reaction enabling the formation of “soft” salts CBPh1-CBPh4.
Figure 1: Visible–NIR spectra of NIR dyes in ACN. A) (1) CBPh1, (2) CBPh2, (3) CBPh3, (4) CBPh4, (5) Ca, (6) ...
Figure 2: Photopolymerization profiles of PETIA monomer under air (acrylate functions conversion vs irradiati...
Figure 3: Photopolymerization profiles of PETIA monomer under air (acrylate functions conversion vs irradiati...
Scheme 6: Pictures of polymers obtained for a thickness of 1.4 mm, using a NIR dye/iod/amine 0.1:3:2, %w/w/w ...
Scheme 7: Proposed mechanism for the photochemical reactivity of NIR dyes in a three-component PIS.
Figure 4: A) Photopolymerization profiles of PETIA/epoxy blend 1:1, w/w under air (acrylate and epoxy functio...
Beilstein J. Org. Chem. 2021, 17, 2077–2084, doi:10.3762/bjoc.17.134
Graphical Abstract
Figure 1: Strategy for the synthesis of glutamate and pyroglutamate derivatives and several natural products ...
Figure 2: Effect of the aryl substituent on reaction efficiency and selectivity.
Figure 3: Proposed transition state model.
Beilstein J. Org. Chem. 2021, 17, 2085–2094, doi:10.3762/bjoc.17.135
Graphical Abstract
Scheme 1: Main routes to SMAHOs.
Scheme 2: Preparation of α-halo-MAHOs.
Scheme 3: Preparation of SMAHOs from Meldrum's acid.
Scheme 4: Saponification of substituted malonates.
Scheme 5: Scope of the mono-esterification of substituted malonic acids. adr = 1:1.
Beilstein J. Org. Chem. 2021, 17, 2095–2101, doi:10.3762/bjoc.17.136
Graphical Abstract
Scheme 1: Schematic representation of the self-initiated photografting and photopolymerization (SIPGP) of 2-h...
Figure 1: A) Graph showing change in the static contact angle with time on a pristine PCL scaffold with a 500...
Figure 2: A) Optical photograph of an SIPGP-coated sample. B) 3D topography reconstruction of the SIPGP-coate...
Figure 3: A) SEM image of pristine, uncoated PCL MEW scaffolds with a hatch spacing of 150 µm × 200 µm and in...